Search

Your search keyword '"Hayem G"' showing total 325 results
Start Over Author "Hayem G"
325 results on '"Hayem G"'

1. Melorheostosis associated with peripheral form spondyloarthropathy: new image with 18-fluoride positron emission tomoscintigraphy coupled to computed tomography

Author

Hassani H, Slama J, Hayem G, Ben Ali K, Sarda-Mantel L, Burg S, and Le Guludec D

Subjects
Diseases of the musculoskeletal system, RC925-935
Abstract

Hakim Hassani1–3, Jérôme Slama1,3, Gilles Hayem4, Khadija Ben Ali1, Laure Sarda-Mantel1,3, Samuel Burg1,3, Dominique Le Guludec1,31Department of Nuclear Medicine, Hôpital Bichat, Paris, France; 2Radiology, Hôpital Robert Debré, Paris, France; 3University Paris VII Denis Diderot, Paris, France; 4Rheumatology, Hôpital Bichat, Paris, FranceAbstract: Melorheostosis is a rare benign bone pathology which can be responsible for incapacitating pain and bone deformations. Its imaging abnormalities are often typical. We describe here the case of a patient with melorheostosis involving the lower limbs, associated with a peripheral form of inflammatory spondyloarthropathy, who underwent 18FNa positron emission tomography coupled to a computed tomography scan. Our objective is to present this new image, to show the value of this new modality and emphasize its advantages compared to the 99mTechnetium bone scan.Keywords: melorheostosis, PET-CT, 18FNa, bone scan, 18F-fluoride

Published
2012

3. SNAPSJIA — Enquête sur les besoins des adolescents et l’opinion des parents sur la santé sexuelle dans l’arthrite juvénile idiopathique

Author

Savel, C., primary, Chausset, A., additional, Berland, P., additional, Guiguet-Auclair, C., additional, Cabane, L., additional, Fautrel, B., additional, Gaudin, P., additional, Guillot, P., additional, Hayem, G., additional, Lafarge, D., additional, Merlin, E., additional, Peziere, N., additional, Sordet, C., additional, Tropé, S., additional, Tournadre, A., additional, Malochet-Guinamand, S., additional, and Cohen, J.D., additional

Published
2023
Full Text
View/download PDF

4. POS0794-HPR SNAPS JIA - SURVEY OF ADOLESCENTS’ NEEDS AND PARENTS’ VIEWS ON SEXUAL HEALTH IN JUVENILE IDIOPATHIC ARTHRITIS

Author

Savel, C., primary, Chausset, A., additional, Berland, P., additional, Guiguet-Auclair, C., additional, Cabane, L., additional, Fautrel, B., additional, Gaudin, P., additional, Guillot, P., additional, Hayem, G., additional, Lafarge, D., additional, Malochet, S., additional, Merlin, E., additional, Peziere, N., additional, Sordet, C., additional, Tropé, S., additional, Tournadre, A., additional, and Cohen, J. D., additional

Published
2023
Full Text
View/download PDF

10. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

Author

Kyriazopoulou, E. Huet, T. Cavalli, G. Gori, A. Kyprianou, M. Pickkers, P. Eugen-Olsen, J. Clerici, M. Veas, F. Chatellier, G. Kaplanski, G. Netea, M.G. Pontali, E. Gattorno, M. Cauchois, R. Kooistra, E. Kox, M. Bandera, A. Beaussier, H. Mangioni, D. Dagna, L. van der Meer, J.W.M. Giamarellos-Bourboulis, E.J. Hayem, G. Netea, M.G. van der Meer, J.W.M. Giamarellos-Bourboulis, E.J. Volpi, S. Sormani, M.P. Signori, A. Bozzi, G. Minoia, F. Aliberti, S. Grasselli, G. Alagna, L. Lombardi, A. Ungaro, R. Agostoni, C. Blasi, F. Costantino, G. Fracanzani, A.L. Montano, N. Peyvandi, F. Sottocorno, M. Muscatello, A. Filocamo, G. Papadopoulos, A. Mouktaroudi, M. Karakike, E. Saridaki, M. Gkavogianni, T. Katrini, K. Vechlidis, N. Avgoustou, C. Chalvatzis, S. Marantos, T. Damoulari, C. Damoraki, G. Ktena, S. Tsilika, M. Koufargyris, P. Karageorgos, A. Droggiti, D.-I. Koliakou, A. Poulakou, G. Tsiakos, K. Myrodia, D.-M. Gravvani, A. Trontzas, I.P. Syrigos, K. Kalomenidis, I. Kranidioti, E. Panagopoulos, P. Petrakis, V. Metallidis, S. Loli, G. Tsachouridou, O. Dalekos, G.N. Gatselis, N. Stefos, A. Georgiadou, S. Lygoura, V. Milionis, H. Kosmidou, M. Papanikolaou, I.C. Akinosoglou, K. Giannitsioti, E. Chrysos, G. Mavroudis, P. Sidiropoulou, C. Adamis, G. Fragkou, A. Rapti, A. Alexiou, Z. Symbardi, S. Masgala, A. Kostaki, K. Kostis, E. Samarkos, M. Bakakos, P. Tzavara, V. Dimakou, K. Tzatzagou, G. Chini, M. Kotsis, V. Tsoukalas, G. Bliziotis, I. Doumas, M. Argyraki, A. Kainis, I. Fantoni, M. Cingolani, A. Angheben, A. Cardellino, C.S. Castelli, F. Serino, F.S. Nicastri, E. Ippolito, G. Bassetti, M. Selmi, C. International Collaborative Group for Anakinra in COVID-19

Abstract

Background: Anakinra might improve the prognosis of patients with moderate to severe COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). We aimed to assess the effect of anakinra treatment on mortality in patients admitted to hospital with COVID-19. Methods: For this systematic review and individual patient-level meta-analysis, a systematic literature search was done on Dec 28, 2020, in Medline (PubMed), Cochrane, medRxiv, bioRxiv, and the ClinicalTrials.gov databases for randomised trials, comparative studies, and observational studies of patients admitted to hospital with COVID-19, comparing administration of anakinra with standard of care, or placebo, or both. The search was repeated on Jan 22, 2021. Individual patient-level data were requested from investigators and corresponding authors of eligible studies; if individual patient-level data were not available, published data were extracted from the original reports. The primary endpoint was mortality after 28 days and the secondary endpoint was safety (eg, the risk of secondary infections). This study is registered on PROSPERO (CRD42020221491). Findings: 209 articles were identified, of which 178 full-text articles fulfilled screening criteria and were assessed. Aggregate data on 1185 patients from nine studies were analysed, and individual patient-level data on 895 patients were provided from six of these studies. Eight studies were observational and one was a randomised controlled trial. Most studies used historical controls. In the individual patient-level meta-analysis, after adjusting for age, comorbidities, baseline ratio of the arterial partial oxygen pressure divided by the fraction of inspired oxygen (PaO2/FiO2), C-reactive protein (CRP) concentrations, and lymphopenia, mortality was significantly lower in patients treated with anakinra (38 [11%] of 342) than in those receiving standard of care with or without placebo (137 [25%] of 553; adjusted odds ratio [OR] 0·32 [95% CI 0·20–0·51]). The mortality benefit was similar across subgroups regardless of comorbidities (ie, diabetes), ferritin concentrations, or the baseline PaO2/FiO2. In a subgroup analysis, anakinra was more effective in lowering mortality in patients with CRP concentrations higher than 100 mg/L (OR 0·28 [95% CI 0·17–0·47]). Anakinra showed a significant survival benefit when given without dexamethasone (OR 0·23 [95% CI 0·12–0·43]), but not with dexamethasone co-administration (0·72 [95% CI 0·37–1·41]). Anakinra was not associated with a significantly increased risk of secondary infections when compared with standard of care (OR 1·35 [95% CI 0·59–3·10]). Interpretation: Anakinra could be a safe, anti-inflammatory treatment option to reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially in the presence of signs of hyperinflammation such as CRP concentrations higher than 100 mg/L. Funding: Sobi. © 2021 Elsevier Ltd

Published
2021

11. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

Author

Kyriazopoulou, E., Huet, T., Cavalli, G., Gori, A., Kyprianou, M., Pickkers, P., Eugen-Olsen, J., Clerici, M., Veas, F., Chatellier, G., Kaplanski, G., Netea, M.G., Pontali, E., Gattorno, M., Cauchois, R., Kooistra, E., Kox, M., Bandera, A., Beaussier, H., Mangioni, D., Dagna, L., Meer, J.W.M. van der, Giamarellos-Bourboulis, E.J., Hayem, G., Kyriazopoulou, E., Huet, T., Cavalli, G., Gori, A., Kyprianou, M., Pickkers, P., Eugen-Olsen, J., Clerici, M., Veas, F., Chatellier, G., Kaplanski, G., Netea, M.G., Pontali, E., Gattorno, M., Cauchois, R., Kooistra, E., Kox, M., Bandera, A., Beaussier, H., Mangioni, D., Dagna, L., Meer, J.W.M. van der, Giamarellos-Bourboulis, E.J., and Hayem, G.

Abstract

Item does not contain fulltext, BACKGROUND: Anakinra might improve the prognosis of patients with moderate to severe COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). We aimed to assess the effect of anakinra treatment on mortality in patients admitted to hospital with COVID-19. METHODS: For this systematic review and individual patient-level meta-analysis, a systematic literature search was done on Dec 28, 2020, in Medline (PubMed), Cochrane, medRxiv, bioRxiv, and the ClinicalTrials.gov databases for randomised trials, comparative studies, and observational studies of patients admitted to hospital with COVID-19, comparing administration of anakinra with standard of care, or placebo, or both. The search was repeated on Jan 22, 2021. Individual patient-level data were requested from investigators and corresponding authors of eligible studies; if individual patient-level data were not available, published data were extracted from the original reports. The primary endpoint was mortality after 28 days and the secondary endpoint was safety (eg, the risk of secondary infections). This study is registered on PROSPERO (CRD42020221491). FINDINGS: 209 articles were identified, of which 178 full-text articles fulfilled screening criteria and were assessed. Aggregate data on 1185 patients from nine studies were analysed, and individual patient-level data on 895 patients were provided from six of these studies. Eight studies were observational and one was a randomised controlled trial. Most studies used historical controls. In the individual patient-level meta-analysis, after adjusting for age, comorbidities, baseline ratio of the arterial partial oxygen pressure divided by the fraction of inspired oxygen (PaO(2)/FiO(2)), C-reactive protein (CRP) concentrations, and lymphopenia, mortality was significantly lower in patients treated with anakinra (38 [11%] of 342) than in those receiving standard of care with or without placebo (137 [25%] of 553; adjusted odds ratio [

Published
2021

12. Épidémiologie des atteintes dermatologiques dans le syndrome de Gougerot-Sjögren : données provenant de trois populations françaises de syndrome de Gougerot-Sjögren primitif (TEARS, ASSESS, DiapSS)

Author

Villon, C., primary, Orgeolet, L., additional, Roguedas, A.-M., additional, Misery, L., additional, Gottenberg, J.-É., additional, Cornec, D., additional, Jousse-Joulin, S., additional, Seror, R., additional, Berthelot, J.-M., additional, Dieude, P., additional, Dubost, J.-J., additional, Fauchais, A.-L., additional, Goeb, V., additional, Hachulla, E., additional, Hatron, P.-Y., additional, Larroche, C., additional, Hayem, G., additional, Le Guern, V., additional, Perdriger, A., additional, Morel, J., additional, Vittecoq, O., additional, Mariette, X., additional, Devauchelle-Pensec, V., additional, and Saraux, A., additional

Published
2020
Full Text
View/download PDF

14. THU0282 EPIDEMIOLOGY OF CUTANEOUS INVOLVEMENT IN SJÖGREN’S SYNDROME: DATA FROM THREE FRENCH POPULATIONS OF PSS (TEARS, ASSESS, DIAPSS)

Author

Villon, C., primary, Orgeolet, L., additional, Roguedas-Contios, A. M., additional, Misery, L., additional, Gottenberg, J. E., additional, Cornec, D., additional, Jousse-Joulin, S., additional, Seror, R., additional, Berthelot, J. M., additional, Dieudé, P., additional, Dubost, J. J., additional, Fauchais, A. L., additional, Goeb, V., additional, Hachlla, E., additional, Hatron, P. Y., additional, Larroche, C., additional, Hayem, G., additional, Le Guern, V., additional, Perdriger, A., additional, Morel, J., additional, Vittecoq, O., additional, Mariette, X., additional, Devauchelle-Pensec, V., additional, and Saraux, A., additional

Published
2020
Full Text
View/download PDF

15. THU0524 FACTORS EXPLAINING PATIENT PERSPECTIVE IN PSORIASIS AND PSORIATIC ARTHRITIS (PSA): THE ROLE OF INFLAMMATION AND STRUCTURAL DAMAGE DETECTED BY ULTRASOUND (THE ECHOPRO STUDY)

Author

Gudu, T., primary, Padovano, I., additional, Mahe, E., additional, Gouze, H., additional, Vidal, F., additional, Bourgault, I., additional, Lara/Gonzalez, L., additional, Guyot, A., additional, Philippe, S., additional, Amy de la Breteque, M., additional, Ruel-Gagné, S., additional, Coronel, L., additional, Costantino, F., additional, Hayem, G., additional, Breban, M., additional, and D’agostino, M. A., additional

Published
2020
Full Text
View/download PDF

16. Facteurs expliquant la perspective du patient dans le psoriasis et le rhumatisme psoriasique : le rôle de l’inflammation et de l’atteinte structurale mesurées par l’échographie

Author

Gudu, T., primary, Mahé, E., additional, Padovano, I., additional, Gouze, H., additional, Vidal, F., additional, Lara Gonzalez, L., additional, Guyot, A., additional, Amy de la Bretèque, M., additional, Saiag, P., additional, Bourgault-Villada, I., additional, Ruel-Gagné, S., additional, Constantino, F., additional, Hayem, G., additional, Breban, M., additional, and D’Agostino, M.-A., additional

Published
2019
Full Text
View/download PDF

22. Myositis in patients with primary Sjögren’s syndrome: data from a French nationwide survey

Author

Houssais, Camille, Noury, J, Allenbach, Y., Gallay, L, Assan, F, Benveniste, O., Broner, J, Duffau, P, Espitia-Thibault, A, Grasland, A, Sanges, S, Hayem, G., Le Guern, V., Martis, N, Marianpillai, K, Mulleman, D., Nocturne, G., Meyer, A., Devauchelle-Pensec, V., Cornec, D., Guellec, D., Centre National de Référence CERAINO, Service de Rhumatologie (Hôpital de la Cavale Blanche), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de Neurologie [Brest], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Service de Médecine Interne - Immunologie Clinique [AP-HP Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Aquitaine’s Care and Research organisation for inflammatory and Immune-Mediated diseases [CHU Bordeaux] (FHU ACRONIM), CHU Bordeaux [Bordeaux], Hôpital Hôtel-Dieu de Nantes - Centre Hospitalier Universitaire de Nantes (Hôpital Hôtel-Dieu de Nantes - CHU de Nantes), Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Claude Huriez [Lille], CHU Lille, Département de Rhumatologie (Rhumato - Ambroise Paré - PARIS), Centre Hospitalier Universitaire Ambroise Paré (CHU Ambroise Paré), Hôpital Cochin [AP-HP], COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Service d'Immunologie [CHU Pitié-Salpétrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de rhumatologie, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), CHU Strasbourg, Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest-Institut Brestois Santé Agro Matière (IBSAM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

23. Épidémiologie et caractérisation des atteintes dermatologiques au cours du syndrome de Gougerot-Sjögren primitif à partir des données de trois cohortes (TEARS, ASSESS, diapSS)

Author

Villon, C., Orgeolet, L., Roguedas, A.M., Misery, L., Gottenberg, J.E., Cornec, D., Jousse-Joulin, S., Seror, R., Berthelot, J.M., Dieude, P., Dubost, J.J., Fauchais, A.L., Goeb, V., Hachulla, E., Hatron, P.Y., Larroche, C., Hayem, G., Guern, V. Le, Perdriger, A., Morel, J., Vittecoq, O., Mariette, X., Devauchelle-Pensec, V., Saraux, A., Service de dermatologie, Hôpital Augustin Morvan-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de dermatologie (Dermato - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de rhumatologie [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Rhumatologie [CHU Gabriel-Montpied], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de Médecine interne A et polyclinique médicale [CHU Limoges], CHU Limoges, Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Rhumatologie - AMIENS (AMIENS - Rhumato), CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de rhumatologie[Lille], Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département de Médecine Interne (DMI - BOBIGNY), chu bobigny, Département de Rhumatologie (Rhumato - Ambroise Paré - PARIS), Centre Hospitalier Universitaire Ambroise Paré (CHU Ambroise Paré), Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], CHU Pontchaillou [Rennes], Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Service de Rhumatologie [CHU Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, and Michel, Geneviève

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

26. European multicentre study to define disease activity criteria for systemic sclerosis. * II. Identification of disease activity variables and development of preliminary activity indexes

Author

Valentini, G, Della Rossa, A, Bombardieri, S, Bencivelli, W, Silman, A J, DʼAngelo, S, Cerinic, M Matucci, Belch, J F, Black, C M, Bruhlmann, P, Czirják, L, De Luca, A, Drosos, A A, Ferri, C, Gabrielli, A, Giacomelli, R, Hayem, G, Inanc, M, McHugh, N J, Nielsen, H, Rosada, M, Scorza, R, Stork, J, Sysa, A, van den Hoogen, F H J, and Vlachoyiannopoulos, P J

Published
2001

27. European multicentre study to define disease activity criteria for systemic sclerosis. * I. Clinical and epidemiological features of 290 patients from 19 centres

Author

Della Rossa, A, Valentini, G, Bombardieri, S, Bencivelli, W, Silman, A J, DʼAngelo, S, Cerinic, M Matucci, Belch, J F, Black, C M, Becvar, R, Bruhlman, P, Cozzi, F, Czirják, L, Drosos, A A, Dziankowska, B, Ferri, C, Gabrielli, A, Giacomelli, R, Hayem, G, Inanc, M, McHugh, N J, Nielsen, H, Scorza, R, Tirri, E, van den Hoogen, F H J, and Vlachoyiannopoulos, P G

Published
2001

31. Anti-heat shock protein 70kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis

Author

Hayem, G., De Bandt, M., Palazzo, E., Roux, S., Combe, B., Eliaou, J.F., Sany, J., Kahn, M.F., and Meyer, O.

Subjects
Immunoglobulin G, Immunoglobulin M, Heat shock proteins -- Measurement, Rheumatoid arthritis -- Physiological aspects, Health
Abstract

The immunoglobulin G (IgG) concentrations which develop in response to the presence of a particular heat shock protein (HSP 90 kDa) are the ones most commonly found in long-term rheumatoid arthritis (RA) patients who have articular erosion. This implies that their presence may be related to the articular prognosis. Also present in long term RA patients are immunoglobulin M (IgM) concentrations to both HSP 90 kDa and HSC 70 kDa, as well as IgGs to both. Study to determine which substance connects to which prognosis should be done.

Published
1999

32. Une dacryoadénite « Stillée »

Author

Huynh, S., primary, Breillat, P., additional, Romero, P., additional, Hayem, G., additional, Padovano, I., additional, Costantino, F., additional, Breban, M., additional, Bourgault Villada, I., additional, and Tourte, M., additional

Published
2017
Full Text
View/download PDF

33. AB1185 Real-life experience and mutual expectations of patients affected with chronical inflammatory rheumatic diseases and their relatives; consequences in patient education: a qualitative study by the proxyric group of the patient education division of french rheumatic disease society

Author

Poivret, D, primary, Untas, A, additional, Boujut, E, additional, Vioulac, C, additional, Delannoy, C, additional, Carton, L, additional, Legoupil, N, additional, Hayem, G, additional, Pouplin, S, additional, Rat, A-C, additional, Quintrec, J-S Giraudet-Le, additional, and Beauvais, C, additional

Published
2017
Full Text
View/download PDF

36. Vécu et attentes réciproques des patients atteints de rhumatismes inflammatoires chroniques (RIC) et de leurs proches et implication pour l’éducation thérapeutique : étude qualitative du groupe ProxyRIC de la section éducation thérapeutique de la SFR

Author

Poivret, D., primary, Untas, A., additional, Boujut, E., additional, Vioulac, C., additional, Delannoy, C., additional, Carton, L., additional, Legoupil, N., additional, Hayem, G., additional, Pouplin, S., additional, Rat, A.C., additional, Giraudet le Quintrec, J.S., additional, and Beauvais, C., additional

Published
2016
Full Text
View/download PDF

37. THU0322 Altered Quality of Life Is Mainly Associated with Patient Reported Outcomes in Primary Sjögren's Syndrome Patients: Data from A Large Therapeutic Trial: Table 1.

Author

Cornec, D., primary, Devauchelle-Pensec, V., additional, Mariette, X., additional, Jousse-Joulin, S., additional, Berthelot, J.-M., additional, Perdriger, A., additional, Puéchal, X., additional, Le Guern, V., additional, Sibilia, J., additional, Gottenberg, J.-E., additional, Chiche, L., additional, Hachulla, E., additional, Hatron, P.-Y., additional, Goeb, V., additional, Hayem, G., additional, Morel, J., additional, Zarnitsky, C., additional, Dubost, J.J., additional, Saliou, P., additional, Pers, J.O., additional, Seror, R., additional, and Saraux, A., additional

Published
2016
Full Text
View/download PDF

39. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients

Author

Seror, R., Gottenberg, J. E., Devauchelle-Pensec, Valérie, Dubost, J. J., Le Guern, V., Hayem, G., Fauchais, Anne-Laure, Goeb, Vincent, Hachulla, Eric, Hatron, P. Y., Larroche, C., Morel, J., Pedriger, A., Puechal, X., Rist, S., Saraux, Alain, Sene, D., Sibilia, J., Vittecoq, Olivier, Zarnitsky, C., Labetoulle, M., Ravaud, P., Mariette, X., Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Régulation de la réponse immune, infection VIH-1 et autoimmunité, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de médecine interne [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Rhumatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Physiopathologie des arthrites, Université Louis Pasteur - Strasbourg I, Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Male, MESH: Aged, MESH: Humans, MESH: Middle Aged, [SDV]Life Sciences [q-bio], Middle Aged, MESH: Male, MESH: Diagnostic Self Evaluation, MESH: France, Diagnostic Self Evaluation, Sjogren's Syndrome, MESH: Sjogren's Syndrome, Outcome Assessment, Health Care, Humans, Female, France, MESH: Female, MESH: Outcome Assessment (Health Care), Aged
Abstract

International audience; OBJECTIVE: The European League Against Rheumatism (EULAR) Sjögren's Syndrome (SS) Disease Activity Index (ESSDAI) and the EULAR SS Patient-Reported Index (ESSPRI) were recently developed. We aimed to determine whether patients' symptoms differed between patients with and without systemic involvement and if the disease-specific indices correlated with each other in primary SS. METHODS: Fifteen French centers included 395 primary SS patients in the Assessment of Systemic Signs and Evolution in Sjögren's Syndrome Cohort. At enrollment, physicians completed the ESSDAI, the SS Disease Activity Index (SSDAI), and the Sjögren's Systemic Clinical Activity Index (SCAI), and patients completed the ESSPRI, the Sicca Symptoms Inventory, and the Profile of Fatigue and Discomfort. All scores were compared between patients with and without systemic involvement. Correlations between scores of systemic activity and patients' symptoms were obtained. RESULTS: At enrollment, 120 (30.4%) patients had never experienced systemic complication and 155 (39.2%) patients and 120 (30.4%) patients had, respectively, only past or current systemic manifestations. Past or current systemic patients had higher levels of symptoms, except dryness. The ESSDAI did not correlate with the patient-scored ESSPRI (rho = 0.06, P = 0.30), whereas the SSDAI and the SCAI, which include subjective items, did correlate (rho = 0.28 and 0.25, respectively; P < 0.0001 for both). CONCLUSION: Alterations of common patient-reported outcomes are present in all patients with primary SS, including those with systemic complications. However, patient symptoms and systemic complications are 2 different facets of primary SS. Therefore, the use of both systemic and patients' indices, such as the ESSDAI and ESSPRI, are useful. Since these 2 facets weakly overlap, one should identify which of both components is the main target of the treatment to test, when designing clinical trials in primary SS.

Published
2013

43. Pupillocynetic activity of substance P in systemic sclerosis

Author

DEL ROSSO, A., Bertinotti, L., Pietrini, U., Messori, A., Casale, R., Generini, S., Cozzi, Franco, Czirjak, L, Drosos, Aa, Dziankowska, B, Ferri, C, Gabrielli, A, Giacomelli, R, Hayem, G, Inanc, M, Mchugh, Nj, Nielsen, H, Scorza, R, Tirri, E, VAN DEN HOOGEN FH, and Vlachoyiannopoulos, P. G.

Published
2003

44. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes

Author

Valentini, G. Della Rossa, A. Bombardieri, S. Bencivelli, W. Silman, A.J. D'Angelo, S. Matucci Cerinic, M. Belch, J.F. Black, C.M. Bruhlmann, P. Czirják, L. De Luca, A. Drosos, A.A. Ferri, C. Gabrielli, A. Giacomelli, R. Hayem, G. Inanc, M. McHugh, N.J. Nielsen, H. Rosada, M. Scorza, R. Stork, J. Sysa, A. Van den Hoogen, F.H.J. Vlachoyiannopoulos, P.J.

Abstract

Objective - To develop criteria for disease activity in systemic sclerosis (SSc) that are valid, reliable, and easy to use. Methods - Investigators from 19 European centres completed a standardised clinical chart for a consecutive number of patients with SSc. Three protocol management members blindly evaluated each chart and assigned a disease activity score on a semiquantitative scale of 0-10. Two of them, in addition, gave a blinded, qualitative evaluation of disease activity ("inactive to moderately active" or "active to very active" disease). Both these evaluations were found to be reliable. A final disease activity score and qualitative evaluation of disease activity were arrived at by consensus for each patient; the former represented the gold standard for subsequent analyses. The correlations between individual items in the chart and this gold standard were then analysed. Results - A total of 290 patients with SSc (117 with diffuse SSc (dSSc) and 173 with limited SSc (lSSc)) were enrolled in the study. The items (including Δ-factors that is, worsening according to the patient report) that were found to correlate with the gold standard on multiple regression were used to construct three separate 10-point indices of disease activity: (a) Δ-cardiopulmonary (4.0), Δ-skin (3.0), Δ-vascular (2.0), and Δ-articular/muscular (1.0) for patients with dSSc; (b) Δ-skin (2.5), erythrocyte sedimentation rate (ESR) >30 mm/1st h (2.5), Δ-cardiopulmonary (1.5), Δ-vascular (1.0), arthritis (1.0), hypocomplementaemia (1.0), and scleredema (0.5) for lSSc; (c) Δ-cardiopulmonary (2.0), Δ-skin (2.0), ESR >30 mm/1st h (1.5), total skin score >20 (1.0), hypocomplementaemia (1.0), scleredema (0.5), digital necrosis (0.5), Δ-vascular (0.5), arthritis (0.5), TLCO

Published
2001

45. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient‐Reported Index: A Complete Picture of Primary Sjögren's Syndrome Patients

Author

Seror, R., primary, Gottenberg, J. E., additional, Devauchelle‐Pensec, V., additional, Dubost, J. J., additional, Le Guern, V., additional, Hayem, G., additional, Fauchais, A.‐L., additional, Goeb, V., additional, Hachulla, E., additional, Hatron, P. Y., additional, Larroche, C., additional, Morel, J., additional, Pedriger, A., additional, Puechal, X., additional, Rist, S., additional, Saraux, A., additional, Sene, D., additional, Sibilia, J., additional, Vittecoq, O., additional, Zarnitsky, C., additional, Labetoulle, M., additional, Ravaud, P., additional, and Mariette, X., additional

Published
2013
Full Text
View/download PDF

46. OP0114 Inefficacy of Hydroxychoroquine in Primary Sjögren’s Syndrome: Results at 12 Months of the Randomized Placebo-Controlled Trial of Plaquenil in Primary Sjögren’s Syndrome

Author

Gottenberg, J. E., primary, Ravaud, P., additional, Puechal, X., additional, Le Guern, V., additional, Sibilia, J., additional, Goeb, V., additional, Larroche, C., additional, Dubost, J. J., additional, Rist, S., additional, Saraux, A., additional, Devauchelle, V., additional, Morel, J., additional, Hayem, G., additional, Hachulla, E., additional, Perdriger, A., additional, Sene, D., additional, Zarnitsky, C., additional, Perrodeau, E., additional, Batouche, D., additional, Furlan, V., additional, Benessiano, J., additional, Seror, R., additional, and Mariette, X., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results